969 results on '"Meier, Friedegund"'
Search Results
2. Clinical Melanoma Diagnosis with Artificial Intelligence: Insights from a Prospective Multicenter Study
3. Prospective multicenter study using artificial intelligence to improve dermoscopic melanoma diagnosis in patient care
4. Personalized identification and characterization of genome-wide gene expression differences between patient-matched intracranial and extracranial melanoma metastasis pairs
5. Using Multiple Dermoscopic Photographs of One Lesion Improves Melanoma Classification via Deep Learning: A Prognostic Diagnostic Accuracy Study
6. Network-based analysis of heterogeneous patient-matched brain and extracranial melanoma metastasis pairs reveals three homogeneous subgroups
7. Early versus late response to PD-1-based immunotherapy in metastatic melanoma
8. Improved survival of advanced melanoma patients receiving immunotherapy with concomitant antithrombotic therapy – A multicenter study on 2419 patients from the prospective skin cancer registry ADOReg
9. A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6
10. Liver-directed treatment is associated with improved survival and increased response to immune checkpoint blockade in metastatic uveal melanoma: results from a retrospective multicenter trial
11. Quality, Understandability and Reliability of YouTube Videos on Skin Cancer Screening
12. Shortened progression free and overall survival to immune-checkpoint inhibitors in BRAF-, RAS- and NF1- (“Triple”) wild type melanomas
13. One Website to Gather them All: Usability Testing of the New German SKin Cancer INFOrmation (SKINFO) Website—A Mixed-methods Approach
14. Second-line therapies for steroid-refractory immune-related adverse events in patients treated with immune checkpoint inhibitors
15. Effects of an immunosuppressive therapy on the efficacy of immune checkpoint inhibition in metastatic melanoma – An analysis of the prospective skin cancer registry ADOREG
16. Real-World efficiency of pembrolizumab in metastatic melanoma patients following adjuvant anti-PD1 treatment
17. Comparison of the efficacy of skin examination using 3D total body photography to clinical and dermoscopic examination
18. Baseline metastatic growth rate is an independent prognostic marker in patients with advanced BRAF V600 mutated melanoma receiving targeted therapy
19. Lower leg reconstruction after resection of a squamous cell carcinoma on necrobiosis lipoidica with a pedicled fibula and an extended anterolateral thigh flap—a case report
20. Patient-specific identification of genome-wide DNA-methylation differences between intracranial and extracranial melanoma metastases
21. Neoadjuvant cemiplimab and surgery for stage II–IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 study
22. Correlation of tumor PD-L1 expression in different tissue types and outcome of PD-1-based immunotherapy in metastatic melanoma – analysis of the DeCOG prospective multicenter cohort study ADOREG/TRIM
23. Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial
24. Practical guidelines for the management of adverse events of the T cell engager bispecific tebentafusp
25. Adjuvant treatment and outcome of stage III melanoma patients: Results of a multicenter real-world German Dermatologic Cooperative Oncology Group (DeCOG) study
26. Deep learning-based scoring of tumour-infiltrating lymphocytes is prognostic in primary melanoma and predictive to PD-1 checkpoint inhibition in melanoma metastases
27. Immune checkpoint inhibition in patients with NRAS mutated and NRAS wild type melanoma: a multicenter Dermatologic Cooperative Oncology Group study on 637 patients from the prospective skin cancer registry ADOREG
28. Identification of Epigenetically Regulated Genes Distinguishing Intracranial from Extracranial Melanoma Metastases
29. Characterisation and outcome of RAC1 mutated melanoma
30. Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: A retrospective multicentre cohort study
31. Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial
32. Model soups improve performance of dermoscopic skin cancer classifiers
33. Whole-exome sequencing in eccrine porocarcinoma indicates promising therapeutic strategies
34. Clinical determinants of long-term survival in metastatic uveal melanoma
35. Influence of adjuvant therapies on organ‐specific recurrence of cutaneous melanoma: A multicenter study on 1383 patients of the prospective DeCOG registry ADOReg.
36. Systemtherapie von Melanom-Hirnmetastasen
37. Decoding molecular programs in melanoma brain metastases
38. An online decision aid for patients with metastatic melanoma—results of the randomized controlled trial „PEF-Immun“
39. Optimizing immune checkpoint blockade in metastatic uveal melanoma: exploring the association of overall survival and the occurrence of adverse events
40. Phase 3 study (PIVOTAL) of neoadjuvant intralesional daromun vs. immediate surgery in fully resectable melanoma with regional skin and/or nodal metastases.
41. Hereditary cutaneous leiomyomatosis and low‐grade glioma due to a fumarate hydratase mutation
42. NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitors
43. Skin cancer classification via convolutional neural networks: systematic review of studies involving human experts
44. A benchmark for neural network robustness in skin cancer classification
45. Clinical characteristics and therapy response in unresectable melanoma patients stage IIIB-IIID with in-transit and satellite metastases
46. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial
47. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
48. Combining CNN-based histologic whole slide image analysis and patient data to improve skin cancer classification
49. Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy – A multicentre study of 90 patients from the German Dermatooncology Group
50. Leptomeningeal disease from melanoma—Poor prognosis despite new therapeutic modalities
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.